Top Story

Target-specific oral anticoagulants reduced risk for bleeding in VTE, atrial fibrillation

September 30, 2014

Target-specific oral anticoagulants reduced the risk for major, fatal and intracranial bleeding compared with vitamin K antagonists in patients with venous thromboembolism or atrial fibrillation, according to results of a meta-analysis.

Results also showed target-specific oral anticoagulants did not increase the risk for gastrointestinal bleeding.

figure Meeting News CoveragePerspective

SECURITY: 6-month DAPT performed similar to 12 months with DES implantation

September 30, 2014
WASHINGTON — The use of a 6-month vs. 12-month regimen of dual antiplatelet therapy yielded comparable outcomes after the implantation of a second-generation…
Meeting News Coverage

Rivaroxaban reduced VTE recurrence, major bleeding in patients with cancer

September 28, 2014
Rivaroxaban demonstrated comparable efficacy and a better safety profile compared with standard therapy in patients with venous thromboembolism and cancer, according to…
figure Meeting News CoveragePerspective

BRIGHT: Bivalirudin outperformed heparin alone, heparin plus tirofiban in PCI

September 26, 2014
WASHINGTON — Bivalirudin was superior to both heparin alone and heparin plus tirofiban in patients with acute MI undergoing coronary intervention, concluded…
CME
figure

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »

Filter By:

In the Journals

Target-specific oral anticoagulants reduced risk for bleeding in VTE, atrial fibrillation

September 30, 2014
Target-specific oral anticoagulants reduced the risk for major, fatal and intracranial bleeding compared with vitamin K antagonists in patients with…
figure Meeting News Coverage Perspective

SECURITY: 6-month DAPT performed similar to 12 months with DES implantation

September 30, 2014
WASHINGTON — The use of a 6-month vs. 12-month regimen of dual antiplatelet therapy yielded comparable outcomes after the implantation of a…
Meeting News Coverage

Rivaroxaban reduced VTE recurrence, major bleeding in patients with cancer

September 28, 2014
Rivaroxaban demonstrated comparable efficacy and a better safety profile compared with standard therapy in patients with venous thromboembolism and…
figure Meeting News Coverage Perspective

BRIGHT: Bivalirudin outperformed heparin alone, heparin plus tirofiban in PCI

September 26, 2014
WASHINGTON — Bivalirudin was superior to both heparin alone and heparin plus tirofiban in patients with acute MI undergoing coronary…
figure Editorial Publication Exclusive

The changing face of our major meetings: Evolution or revolution?

HemOnc Today, September 10, 2014
John Sweetenham, MD, PhD
One morning in late July, I was poised over my laptop at exactly 9 a.m. Mountain time, ready for the ASH Annual Meeting and Exposition registration…
In the Journals

Lexaptepid shows promise for anemia of inflammation treatment

September 9, 2014
The experimental drug lexaptepid achieved clinically relevant results in inhibiting the hepcidin production involved in anemia of inflammation…
figure In the Journals Perspective

HLA-matched donors available for most HSCT candidates

HemOnc Today, September 10, 2014
A majority of hematopoietic stem-cell transplantation candidates who do not have related donors have suitable adult donors or cord-blood units…
figure In the Journals

Anemia treatment not beneficial after brain injury

August 27, 2014
Two frequently used anemia treatments did not improve short-term neurocognitive outcomes in patients who experienced a traumatic brain injury…
FDA approvals

FDA expands approval of Promacta

August 26, 2014
The FDA today expanded the improved indications for eltrombopag to include treatment of patients with severe aplastic anemia who demonstrated an…
figure In the Journals

Aspirin reduced risk for recurrent VTE

August 25, 2014
Aspirin after anticoagulation reduced the risk for recurrent venous thromboembolism by more than one-third in patients with a first unprovoked VTE…
More Headlines »